XEN1101 + itraconazole

**XEN1101 + itraconazole** is a combination of two distinct pharmaceutical agents: - **XEN1101** is a novel, small molecule, selective potassium channel opener (Kv7.2/Kv7.3, also known as KCNQ2/3), acting as a positive allosteric modulator. It is being developed as an adjunctive treatment for focal onset seizures (FOS) in adults with epilepsy. XEN1101 rapidly reduces cortical excitability and seizure frequency, with once-daily oral dosing and no need for titration. It can be started at an effective dose immediately and has a long half-life, leading to consistent drug levels and a “grace period” for missed doses. Its structure is distinct from ezogabine and it presents low risk for tissue discoloration or pigment-related adverse effects[3][5][7]. - **Itraconazole** is an antifungal agent that inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, through inhibition of the enzyme lanosterol 14α-demethylase (a cytochrome P450 enzyme). It is used in the treatment and prevention of a variety of fungal infections. No combination product currently exists under this exact name or is described in any clinical study; thus, **XEN1101 + itraconazole** should be interpreted as a hypothetical or investigational combination of an anticonvulsant and an antifungal drug.

Brand names

XEN1101 + itraconazole

Other names

XEN1101 + itraconazole